Few molecules generate as much longevity buzz as NAD+ (nicotinamide adenine dinucleotide) and the sirtuin enzymes it powers. Together they sit at the crossroads of metabolism, stress response, and DNA maintenance, which is why they feature heavily in aging research and in supplement marketing alike. Separating the established biology from the hopeful extrapolation is worthwhile.

What NAD+ actually does

NAD+ is a coenzyme present in every cell. It shuttles electrons during the reactions that convert food into usable energy, making it indispensable to mitochondrial function. Beyond energy, NAD+ serves as a substrate consumed by several enzyme families, including sirtuins and the DNA-repair enzyme PARP. Because it is used up in these reactions, cells must continually regenerate and synthesize it.

Research in animals and some human tissue samples suggests NAD+ availability declines with age. Proposed reasons include increased consumption by repair and inflammatory enzymes and reduced synthesis. Lower NAD+ is associated with impaired mitochondrial performance in preclinical models.

Sirtuins as NAD+-dependent regulators

Sirtuins are a family of enzymes (SIRT1 through SIRT7 in humans) that remove chemical tags from proteins, thereby influencing gene expression, DNA repair, and metabolic regulation. Crucially, they require NAD+ to function, so their activity is tied to the cell's metabolic state. When NAD+ is abundant, sirtuins can act; when it is scarce, their activity falls.

The link between NAD+ and sirtuins means metabolism and stress-response signaling are chemically coupled.

In yeast, worms, and mice, boosting sirtuin activity has been associated with improved stress resistance and, in some experiments, extended lifespan. These findings drove enormous interest, though the effects have proven context-dependent and sometimes difficult to reproduce across labs.

What human evidence shows

Precursors such as nicotinamide riboside and nicotinamide mononucleotide can raise blood NAD+ markers in human trials, which is a genuine, replicated finding. What remains unproven is whether raising these markers translates into meaningful improvements in healthspan, disease risk, or aging outcomes in people. Trials to date are generally small, short, and focused on surrogate measures rather than long-term health endpoints.

  • NAD+ is essential to energy metabolism and repair signaling.
  • Sirtuins depend on NAD+ and regulate multiple stress pathways.
  • Lifespan effects are strongest in simple model organisms.
  • Human benefit beyond raising NAD+ levels is not established.

The NAD+ and sirtuin story illustrates a recurring pattern in longevity science: compelling mechanisms and striking animal data that outpace the human evidence. The underlying biology is real and important, but the leap from raising a biomarker to slowing aging is exactly the step that rigorous trials must still test.

For research and educational purposes only. This is not medical advice.